Highlights from ICML 2017: The CLL2-BAG study
The potential of biosimilar rituximab: reducing budgets and increasing access to treatment
Summary of CLL trials presented at ASH 2016
EMMA 2017 meeting in Madrid: what to expect
Is double autologous transplantation in multiple myeloma superior in the age of new agents?